The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2024 | Approaching treatment selection and sequencing with the recent influx of BTK inhibitors in CLL
Dima El-Sharkawi, MBBS, MA, PhD, MRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK, shares insight into the best way to sequence currently available BTK inhibitors (BTKi) when treating patients with chronic lymphocytic leukemia (CLL). In patients who lose response to a first- or second-generation BTKi (ibrutinib, acalabrutinib, or zanubrutinib), the reversible BTKi pirtobrutinib can be used. Following this, other approaches for targeting BTK, such as using BTK degraders, may show promise for patients who fail on pirtobrutinib. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Abbvie; AstraZeneca; Beigene; Gilead, Janssen; Lily; Roche; Takeda
Conference/ Travel support: Abbvie; Novartis; Roche
Ad boards: Abbvie; ASTEX; AstraZeneca; Beigene; Janssen; Kyowa Kiirin
